Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00931918 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
A Phase 2 study of Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL), sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT00931918 is a Phase 2 study of Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 206 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT00931918, a Phase 2 study of Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL), has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label, multi-center, phase 2 study of RCHOP with or without VELCADE in adult patients with previously untreated non-(Germinal B-Cell-like) GCB Diffuse Large B-cell Lymphoma (DLBCL). The study will determine whether the addition of VELCADE to RCHOP improves progression-free survival (PFS) in patients with non-GCB DLBCL.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Vincristine
- DRUG Bortezomib
Study Locations (20)
California
- Tower Cancer Research Foundation - Beverly Hills
- Fountain Valley Regional Hospital - Fountain Valley
- St. Jude Heritage Healthcare - Fullerton
- Moores Cancer Center- UCSD - La Jolla
- Antelope Valley Cancer Center - Lancaster
- Loma Linda University Cancer Center - Loma Linda
- University of Southern California - Los Angeles
- Jonsson Comprehensive Cancer Center - Los Angeles
- TORI- Central Pharmacy - Los Angeles
- TORI- Central Regulatory - Los Angeles
- Oncology Care Medical Associates - Montebello
- Bay Area Cancer Research Group - Pleasant Hill
- Wilshire Oncology Medical Group - Rancho Cucamonga
- Sharp Healthcare - San Diego
- Central Coast Medical Oncology Corporation - Santa Maria
Florida
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists & Research Institute - Gainsville
- Alves/ Domenech Oncology-Hematology Clinic - Hollywood
- Florida Cancer Institute ATI - New Port Richey
Colorado
- Rocky Mountain Cancer Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00931918
The ClinicalTrials.gov registry entry for NCT00931918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00931918 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00931918 about?
NCT00931918 is a clinical study titled "Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients". This is a randomized, open-label, multi-center, phase 2 study of RCHOP with or without VELCADE in adult patients with previously untreated non-(Germinal B-Cell-like) GCB Diffuse Large B-cell Lymphoma (DLBCL). The study will determine whether the addition of VELCADE to RCHOP improves progression-free...
What is the current status of trial NCT00931918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2009-10. Estimated completion is 2015-08.
What conditions does trial NCT00931918 study?
This clinical trial studies the following conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL).
What interventions are being tested in trial NCT00931918?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Vincristine (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00931918?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00931918 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.